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Background: To analyse the prognostic significance of preoperative C-reactive protein (CRP) serum level in patients
with upper urinary tract urothelial carcinoma (UUT-UC).
Methods: We evaluated 158 UUT-UC patients who had undergone surgery in the University Hospital of Hannover
(MHH). 143 (89.4%) suffered from cancer in the renal pelvis, 13 (8.1%) patients presented with tumour located in the
ureter. A preoperative CRP value was available for 115 patients. The mean (median) follow-up for these patients was
28.3 (15.1) months.
Results: The median (mean) CRP value of all evaluable patients was 10.0 (40.7) mg/l. The CRP-level, stratified into
two subgroups (CRP ≤5 vs. >5 mg/l), correlated significantly with muscle invasive tumour stage (36.4 vs. 78.9%;
p<0.001), the risk of presenting nodal disease (4.5 vs. 26.8%; p=0.002) and distant metastasis (2.3 vs. 16.9%; p<0.016).
The Kaplan-Meier 5-year cancer specific survival (CSS) rates were 54.2 and 26.4% for patients with preoperative CRP
levels ≤ and >5 mg/l, respectively (p<0.006). Next to age and the presence of metastasis, multivariate analysis also
identified CRP as a continuous variable as an independent prognosticator for CSS.
Conclusions: A high preoperative serum CRP level is associated with locally advanced and metastatic disease in
patients with UUT-UC. Its routine use could allow better risk stratification and risk-adjusted follow-up of UUT-UC
patients.
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Upper urinary tract urothelial carcinoma (UUT-UC) ac-
counts for 5–7% of all urothelial malignancies in adults;
and its incidence increased steadily over the last 20 years
[1]. Thus UUT-UC, compared to bladder cancer, is still
relatively uncommon; however, it is often a highly ag-
gressive tumour and the prognosis, in general, is poorer
than that for urothelial cancer of the bladder [1].
As patients' clinical courses vary and are difficult to
predict, the stratification of patients to appropriate postop-
erative surveillance programs and different therapeutic
strategies tailored to the individual risk of cancer progres-
sion is helpful. Tumour stage, pathological grade, tumour* Correspondence: steffens.sandra@mh-hannover.de
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reproduction in any medium, provided the orlocation, lymph node involvement, lymphovascular inva-
sion and surgical procedure are known prognostic factors
[2-6]. However, all of these are postoperative factors, there-
fore identifying preoperative prognostic factors, including a
serum biomarker, would allow a better therapeutic ap-
proach. Particularly biomarkers in body fluids could offer
the opportunity for more objective and reproducible meas-
urement and risk stratification prior to surgery.
C-reactive Protein (CRP) is an acute phase protein
produced almost exclusively by the liver. CRP plasma
levels can increase up to 1000-fold in response to micro-
bial infection, trauma, infarction, autoimmune, or malig-
nant diseases. Elevated CRP levels can be a result of an
underlying cancer and a premalignant state, respectively,
as well as due to tumour growth associated tissue in-
flammation. A study published in 2009 by Allin et al. [7]
involving 10,408 individuals showed that elevated CRP isd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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colorectal malignancies. Furthermore, an elevated CRP
level was associated with an early death, even in patients
without metastases [7].
McArdle et al. [8] were able to show that CRP, next to
prostate specific antigen (PSA), could serve as an add-
itional independent prognostic marker for tumour-specific
survival in metastatic castration-resistant prostate cancer.
Furthermore, several studies published in recent years
including from 40 up to 1,161 patients indicated that the
preoperative CRP level could also be associated with
RCC-specific mortality [9-17].
Concerning urothelial carcinoma, Trichopoulos et al.
[18] revealed that elevated CRP can be related to a
higher risk of developing bladder cancer. In patients
with advanced bladder cancer undergoing chemotherapy
elevated CRP levels were shown to be associated with a
poor clinical outcome [19]. To our knowledge only one
study published so far was able to show that in patients
undergoing surgery for UUT-UC an increased CRP level
seems to be asscociated with poor survival [20]. There-
fore, in this study including 115 patients, we validated
the potential pre-operative prognostic significance of
CRP in patients undergoing surgery for UUT-UC.
Methods
Patients and tumour characteristics
This study included 158 patients with complete patient
and tumour specific characteristics who underwent sur-
gery form 1981–2011 for UUT-UC at the Hannover
University Medical Centre (MHH). None of the patients
had received preoperative chemotherapy. The regional
lymph nodes were dissected in patients with enlarged
nodes during surgery or in case of pathological findings
on the pre-operative CT scan; an extended lymphade-
nectomy was not used routinely. 43 patients were ex-
cluded because their preoperative CRP levels were
unavailable. The ethical committee of the MHH ap-
proved the study. The histological tumour subtype was
determined according to the 1997 UICC classification.
Staging was based on the 2002 TNM classification. In-
formation on patients´ and tumour characteristics, such
as age, sex, stage, presence of regional lymph node or
distant metastases, histological subtype, tumour grade
according to the Who classification, and CRP-value, was
obtained from our computerized institutional databases.
The pre-operative CRP-value was categorized into two
groups CRP≤5 mg/l and >5 mg/l according to the sug-
gestion of Saito et al. [20].
Follow up
After surgery patients underwent urinary cytology and
cystoscopy every 3 months for the first 2 years. In addition,
CT and/or MRI were used every 6 months for 5 years andannually thereafter. The duration of the follow-up was cal-
culated from date of surgery to the date of death or last
follow-up. Death was assessed as either cancer-related or -
unrelated. The primary end point of this study was cancer-
specific survival (CSS). Information about the exact date as
well as cause of death for each patient was received from
the patient’s general practitioner, a close family member or
the patient’s hospital records if she/he had been followed
up or died in our institution. Follow-up assessment ended
in October 2011. Until then, all patients’ data were updated
at least every 12 months on a regular basis.
Statistical methods
Continuous variables were reported as mean value and
standard deviation (SD) or median value and interquartile
ranges (IQR) in the case of parametric or non-parametric
distribution, respectively. Chi2 and Fisher’s exact tests
were conducted to assess correlations of nominal covari-
ate distributions and CRP-groups. The t-test and ANOVA
(in case of parametric) or the Mann–Whitney-U-test (in
case of non-parametric distribution) was applied to com-
pare metric variables between two or more subgroups.
Receiver operation characteristics (ROC) curves were
constructed to assess the potential of preoperative CRP
to predict muscle invasive disease, poor differentiation,
and the presence of metastasis at the time of surgery.
Kaplan-Meier estimates of survival time were calcu-
lated, and subgroups were compared by the log rank test
statistic. Multivariate Cox regression models were used
to assess the association between survival and CRP-levels
adjusted for different clinical and patient covariates
(i.e., age, sex, tumour stage and grade, and metastatic
status). SPSS 19.0 was used for statistical assessment.
In all tests, a two-sided p<0.05 was considered to in-
dicate significance.
Results
Our patient population with an available pre-surgical
CRP value consisted of 83 (72.2%) men and 32 (27.8%)
women had a mean (median) age of 65.6 (66.8) years
(34–90). The median body mass index (BMI) for all pa-
tients was 25.0 kg/m2 (IQR, 22.6 – 28.1). 107 (93.9%)
suffered from cancer in the renal pelvis, 7 (6.1%) patients
presented with tumour located in the ureter. Detailed
patients’ and tumour characteristics including stage and
grade are summarized in Table 1.
The median / mean follow-up was 15.1 / 28.3 months
(IQR, 7.2 – 37.7). By the last day of data acquisition, 39
(33.9%) patients had died from their tumour disease.
Clinical parameters
The mean (median) pre-operative CRP value of all 115
evaluable patients was 40.7 (10.0) mg/l. The mean (me-
dian) CRP value in the two subgroups (CRP≤5, n=44
Table 1 Association between different patient and








62.8 (±12.2) 67.3 (±11.8) 0.054 t-test
BMI, mean
[kg/m2] ±SD
25.7 (±3.8) 25.4 (±4.2) 0.67 t-test
Sex 0.67 Fisher
female 11 (25.0) 21 (29.6)
male 33 (75.0) 50 (70.4)
Location 0.71 Fisher
renal pelvis 42 (95.5) 65 (92.9)
ureter 2 (4.5) 5 (7.1)
Stage Fisher
superficial (pT<2) 28 (63.6) 15 (21.1) <0.001
invasive (≥pT2) 16 (36.4) 56 (78.9)
Metastasis 1 0.001 Fisher
N / M - 41 (93.2) 48 (67.6)
N / M + 3 (6.8) 23 (32.4)
Grade <0.001 chi-square
G1 12 (27.3) 7 (9.9)
G2 24 (54.5) 18 (25.4)
G3 8 (18.2) 46 (64.8)
1 at time of surgery.
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respectively. Both groups were comparable concerning
the distribution of sexes (p=0.67; Fisher’s exact test,
Table 1), the BMI value (p=0.67; t-test) and tumour loca-
tion (p=0.71, Fisher’s exact test; Table 1) as well as age,
even though patients with a CRP >5 mg/l tended to be
older (p=0.054; t-test).
Tumour-specific parameters
The CRP-level correlated significantly with the tumour
stage: 36.4 and 78.9% of all patients with a CRP ≤
and >5 mg/l suffered from muscle invasive disease (pT≥2)
at the time diagnosis (p<0.001, Fisher’s exact test). Ac-
cordingly, the median CRP value was significantly lower
in those patients with superficial compared to invasive
cancer (4.0 vs. 19.5 mg/l; p<0.001, Mann–Whitney-U
test). The risk of presenting nodal disease (p=0.002,
Fisher’s exact test) or distant metastasis (p=0.016, Fisher’s
exact test; Table 1) also increased significantly in patients
with a CRP value >5 mg/l. Moreover, elevated CRP-levels
were found in 9.9, 25.4 and 64.8% of patients with G1, G2
and G3 tumours, respectively (p<0.001, Chi2 test).
Receiver-operating characteristic (ROC) analysis
Applying ROC analyses, the CRP value as a continuous
metric variable exhibited an AUC (95% CI) of 0.73(0.64 – 0.83; p<0.001) for the presence of metastatic disease
at the time of surgery (lymph node or visceral metastasis),
of 0.76 (0.67 – 0.85; p<0.001) for poor tumour differenti-
ation (G3), and of 0.70 (0.60 – 0.80; p<0.001) for the pres-
ence of a muscle invasive stage.
Clinical course and oncological outcome
The median survival for all evaluable patients was
50.1 months (Kaplan-Meier). Applying univariate Cox-
Regression calculation, an elevated BMI (p=0.75) or male
sex (p=0.11) did not predict CSS. In contrast, T-stage (HR
1.24, 95% CI 1.05-1.48, p=0.014), the presence of metasta-
ses at the time of surgery (HR 3.91, 95% CI 1.90-8.04,
p>0.001), tumour grade (HR 1.87, 95% CI 1.14-3.07,
p=0.013), age in years (HR 1.06, 95% CI 1.03-1.09,
p<0.001) and a CRP-value >5 mg/l (HR 2.67, 95% CI 1.28-
5.54, p=0.009) were associated with poor CSS. Accord-
ingly, the Kaplan-Meier 5-year CSS rates for patients with
a CRP ≤ and > 5 mg/l were 54.2 and 26.4%, respectively
(p=0.006, log rank; Figure 1).
Multivariate analysis including age and CRP as con-
tinuous metric parameters as well as sex, tumour stage,
and differentiation identified the presence of lymph node
and/or distant metastasis at the time of surgery (HR
4.24, 95% CI: 1.89-9.52; p<0.001, Cox regression), age
[years] (HR 1.06, 95% CI 1.03-1.10, p<0.001), and the
CRP-value [mg/l] (HR 1.01, 95% CI 1.004-1.02, p=0.001)
as independent prognosticators for cancer-specific sur-
vival in patients with UUT-UC.
Discussion
Only recently, Saito et al. [20] presented a study includ-
ing 130 patients suggesting for the first time that ele-
vated CRP is associated with a poor prognosis in
patients with UUT-UC. The authors recommended
stratifying patients according to the CRP cut-off values
of 5.0 mg/l. In this study, we could confirm that a CRP
value of >5.0 mg/l was significantly associated with
muscle invasive disease (pT≥2), lymph node metastasis,
distant metastasis and poor tumour differentiation. Fur-
thermore, a high CRP value was associated with poor
cancer specific survival in patients undergoing resection
for UUT-UC. These results confirmed the impact of cir-
culating CRP levels on the staging and prognosis of pa-
tients with UUT-UC.
Saito et al. [20] were able to identify an elevated CRP
and lymph node invasion as an independent preopera-
tive risk factor for disease-specific death. In this study
multivariate analysis including age, sex, histological sub-
type, tumour stage, and differentiation identified the
presence of lymph node and/or distant metastasis and
both an elevated CRP value and age, at least as continu-
ous metric parameters, as independent predictors for
CSS in patients with UUT-UC.
Figure 1 Cancer-specific survival (Kaplan-Meier) for all UUT-UC patients plotted against the pre-operative CRP-group. The 5-year survival
rates were 54.2 and 26.4%, respectively, for all evaluable patients (n=77) with a CRP of ≤5 mg/l (n=36) and >5 mg/l (n=41), respectively (p=0.006,
log rank).
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more objective and reproducible measurement prior to
tumour surgery, the use of CRP as a worldwide well-
standardized parameter, should not be underestimated.
Rather than tumour tissue-based factors, it can easily be
implemented as a prognostic factor in addition to
tumour stage and grade, to more accurately stratify pa-
tients with UUT-UC. However, as CRP is a not a specific
biomarker its use is limited in patients with other dis-
eases in which CRP might be elevated, e.g. inflammatory
or cardiovascular disease.
Systemic inflammatory response is of considerable im-
portance in the relationship between the tumour, the
host and outcome in patients with cancer. Elevation of
the serum CRP level can be explained as part of a
paraneoplastic syndrome [21]. It is likely that the associ-
ation with muscle invasive disease among patients with
high serum CRP levels may be due to tumor spread that
cannot be detected either by routine imaging studies or
by pathologic examinations.
However, the mechanism of high CRP in patients with
solid tumors, e.g. urogential or gastrointestinal cancer,
has not been determined yet. Several explanations have
been proposed such as that CRP could directly impair
immune functions [22-24] allowing unrestrained tumour
growth. Alternatively, CRP is a component of the acute-
phase response mainly induced by interleukin-6, and
thus has the potential to enhance or inhibit theproliferation of carcinoma cells. Therefore, an elevated
CRP might indicate tumours capable of producing sig-
nificant amounts of proinflammatory cytokines, in par-
ticular interleukin-6 [25,26].
In genito-urinary malignancies, interleukin-6 functions
as an autocrine growth factor for renal cell and prostate
cancer [27-30]. Previously, we reported that a high pre-
operative serum CRP level is an independent predictor
of poor survival in patients with renal cell cancer [17].
Trichopoulos et al. [18] revealed that elevated CRP can
be related to a higher risk of developing bladder cancer.
Experimental studies have shown that malignant
urothelial cells acquire an additional growth advantage
over benign cells by producing interleukin-6 [30]. These
findings support the view that a systemic inflammatory
response of the host indicates an aggressive nature of
UUT-UC.
There are several limitations in our study that need to
be acknowledged. The major limitation of this study is
its retrospective design therefore the drawn conclusions
have to be treated with reservation and need to be con-
firmed in prospective settings. Further limitations are
the relative small number of patients and the short mean
follow-up of only 28 month. In addition, surgical series
have obvious inherent and selection biases as they only
evaluate patients undergoing surgery and patient’s
deemed nonsurgical candidates, for metastatic disease or
other reasons, are not included. Finally, our cohort
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cancer than with UC of the ureter, this imbalance might
have biased our analysis.
Conclusions
This study confirms that a high preoperative CRP-level
is significantly associated with muscle invasive and meta-
static disease and that CRP can serve as an independent
predictor of CSS. Its routine use could allow better
risk stratification and risk-adjusted follow-up for pa-
tients with upper urinary tract urothelial carcinoma.
However, our result should be validated in larger, multi-
center studies.
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